vida: extract claims from 2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits

- Source: inbox/queue/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/hospital-price-transparency-produces-cost-reductions-only-for-self-pay-elective-procedures-not-insured-patients.md

@@ -17,3 +17,10 @@ related: ["value-based-care-transitions-stall-at-the-payment-boundary-because-60
 # Hospital price transparency rules produce measurable cost reductions only for self-pay patients seeking elective procedures while insured patients show no behavioral change because insurance insulates them from marginal cost
 
 Multiple 2025 studies show hospital price transparency compliance remains poor (55% of hospitals had not posted readable price files 6 months after rule took effect) and market impact is highly selective. Pan & Yaraghi's SAGE 2025 analysis found that transparency 'does NOT broadly reduce hospital charges' but 'DOES lead to lower charges for self-pay patients opting for elective procedures who are sensitive to price and can shop.' Critically, 'behavioral changes were NOT observed for insured patients.' The mechanism is structural: insured patients typically owe copay/deductible amounts, not full prices, so price transparency doesn't change their marginal cost. Provider networks (HMO, narrow network plans) further limit patient choice regardless of price knowledge. Emergency care, specialist referrals, and surgery remain non-shoppable. Brookings estimated potential savings of $80.1 billion using a 40% reduction in shoppable service expenditures, but this assumes behavioral change that hasn't materialized for the insured majority. The evidence shows market competition works only at the margins (self-pay elective procedures) while the bulk of healthcare spending remains structurally insulated from consumer price pressure. FFS payment incentives operate at the payer-provider level, not the consumer level, and price transparency doesn't touch this layer.
+
+
+## Supporting Evidence
+
+**Source:** MedCity News context, March 2026
+
+Broader research cited in source shows hospital price transparency rules have limited impact on insured patients, with consumer price pressure limited to self-pay elective procedures only. Insured patients (the majority) show no behavioral changes from price transparency, paralleling the DTE pricing story where headline list price cuts don't translate to net price reductions for insured populations.

domains/health/manufacturer-direct-to-employer-channels-challenge-pbm-intermediation-through-price-compression.md

@@ -67,3 +67,10 @@ Both Novo Nordisk (via 9amHealth No-Barriers Bundle and Waltz Health DTE program
 **Source:** Medical Economics, November 2025
 
 Cost Plus Drugs' partnership with Humana for 'end-to-end employer prescription solutions' represents another direct-to-employer channel that bypasses traditional PBM spread pricing through transparent cost-plus-15% pricing. However, the fact that Cost Plus chose to partner with Humana's CenterWell Pharmacy rather than build independent distribution infrastructure suggests that direct channels still require incumbent partnerships for scale, limiting the disintermediation potential.
+
+
+## Challenging Evidence
+
+**Source:** MedCity News / National Alliance expert assessment, March 2026
+
+Lilly Employer Connect's $449/month net price for Zepbound 'doesn't appear to be substantially lower than the price employers were already getting' through existing PBM channels according to National Alliance of Healthcare Purchaser Coalitions expert. Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of US prescription claims. The DTE channel represents a governance shift (manufacturers as direct participants in employer benefit design) rather than price disruption.

inbox/archive/health/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md

@@ -56,7 +56,7 @@ Eli Lilly launched Employer Connect on March 5, 2026 — a direct-to-employer pl
 
 **KB connections:**
 - Connects to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — DTE reduces list price but doesn't change the chronic use economics
-- Connects to [[value-based care transitions stall at the payment boundary]] — DTE is a distribution innovation, not a payment model change; FFS incentive structure persists
+- Connects to value-based care transitions stall at the payment boundary — DTE is a distribution innovation, not a payment model change; FFS incentive structure persists
 
 **Extraction hints:**
 - CLAIM: "Manufacturer direct-to-employer GLP-1 channels represent a governance shift rather than structural disruption — the $449 DTE price is not substantially below existing PBM net prices, and Big Three PBMs still control 80% of US prescription claims"

inbox/queue/2026-04-29-lilly-employer-connect-not-revolutionary-dte-limits.md

@@ -1,69 +0,0 @@
----
-type: source
-title: "Lilly Employer Connect Adds Flexibility for Employers But Isn't Revolutionary, Expert Says"
-author: "MedCity News / Fierce Healthcare / Sequoia"
-url: https://medcitynews.com/2026/03/lilly-employers-glp1s/
-date: 2026-03-05
-domain: health
-secondary_domains: []
-format: article
-status: unprocessed
-priority: medium
-tags: [GLP-1, direct-to-employer, DTE, PBM, Lilly, employer-coverage, market-competition]
-intake_tier: research-task
----
-
-## Content
-
-Eli Lilly launched Employer Connect on March 5, 2026 — a direct-to-employer platform offering Zepbound at $449/month net price (vs. $1,000+ retail) through 18 program administrators. Key expert assessments:
-
-**MedCity News / National Alliance of Healthcare Purchaser Coalitions expert:**
-- "This isn't revolutionary, but it shows incremental improvements in flexibility for employers seeking to provide access for these expensive drugs."
-- Pricing "doesn't appear to be substantially lower than the price employers were already getting" through existing channels
-- No enrollment projections, adoption targets, or enrollment data provided by Lilly
-
-**Sequoia governance analysis (April 2026):**
-- "This isn't primarily a pricing story. It's a control and governance story."
-- Historically: manufacturers influenced access indirectly through PBMs. Now Lilly is direct participant in employer strategy
-- Introduces new complexity in cost oversight, vendor alignment, and long-term financial accountability
-- Fundamentally shifts how employers engage with drug manufacturers
-
-**Market structure context:**
-- Big Three PBMs (CVS Caremark, OptumRx, Express Scripts) still control approximately 80% of U.S. prescription claims
-- Cost Plus Drugs remains marginal challenger despite growth; partnering WITH Humana CenterWell rather than displacing incumbents
-- 18 administrator partners include: Calibrate, Form Health, Waltz Health, GoodRx — behavioral integration layer, not simple drug delivery
-
-**Coverage landscape:**
-- Only 20% of companies with 200+ workers cover weight loss drugs
-- Only 43% of companies with 5,000+ employees cover weight loss drugs
-- Lilly forecasting 25% revenue growth for 2026 (from all sources, not DTE alone)
-
-**Price transparency parallel (from broader research):**
-- Hospital price transparency rules show limited impact on insured patients
-- Consumer price pressure limited to self-pay elective procedures only
-- Insured patients (the majority) show no behavioral changes from price transparency
-
-## Agent Notes
-
-**Why this matters:** Tests whether market competition mechanisms (DTE, Cost Plus, price transparency) can bypass structural payment misalignment without VBC reform — the core Belief 3 disconfirmation scenario. The "not revolutionary" assessment from the National Alliance expert is the key verdict.
-
-**What surprised me:** Lilly's $449/month price is NOT substantially cheaper than what employers were already getting through rebate structures. The headline price cut ($449 vs. $1,000 list) is misleading — employers with PBM rebate contracts were already at comparable net prices. The DTE story is about GOVERNANCE SHIFT, not price disruption.
-
-**What I expected but didn't find:** Enrollment data, adoption targets, any evidence of scale. Lilly provided none. The DTE channel is launching but has no demonstrated scale yet.
-
-**KB connections:**
-- Connects to [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — DTE reduces list price but doesn't change the chronic use economics
-- Connects to value-based care transitions stall at the payment boundary — DTE is a distribution innovation, not a payment model change; FFS incentive structure persists
-
-**Extraction hints:**
-- CLAIM: "Manufacturer direct-to-employer GLP-1 channels represent a governance shift rather than structural disruption — the $449 DTE price is not substantially below existing PBM net prices, and Big Three PBMs still control 80% of US prescription claims"
-- COMPLICATION: The Sequoia "control and governance" framing suggests DTE may be more significant long-term (manufacturers as active participants in employer benefit design)
-- SCOPE: This is about drug pricing/distribution channels, not about the FFS payment model that Belief 3 describes. DTE doesn't change how hospitals or physicians are paid.
-
-**Context:** Lilly launch announcement March 5, 2026. MedCity expert assessment same week. Sequoia governance analysis April 2026. Represents the state of "market competition as structural bypass" in Q1-Q2 2026.
-
-## Curator Notes
-
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
-WHY ARCHIVED: Direct evidence for Belief 3 disconfirmation attempt — does market competition bypass structural misalignment? Answer: no. DTE is incremental governance shift, not structural disruption. PBMs control 80% of claims. Price transparency is limited to self-pay.
-EXTRACTION HINT: Extractor should distinguish between the two market competition arguments: (1) drug pricing channels (DTE, Cost Plus) vs. (2) healthcare payment model (FFS vs. VBC). They're separate layers. DTE disrupts drug distribution slightly but doesn't touch FFS payment incentives.